Iovance Biotherapeutics (IOVA) Enterprise Value (2016 - 2025)
Historic Enterprise Value for Iovance Biotherapeutics (IOVA) over the last 14 years, with Q3 2025 value amounting to -$300.8 million.
- Iovance Biotherapeutics' Enterprise Value fell 8322.76% to -$300.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$300.8 million, marking a year-over-year decrease of 8322.76%. This contributed to the annual value of -$323.8 million for FY2024, which is 1569.1% down from last year.
- As of Q3 2025, Iovance Biotherapeutics' Enterprise Value stood at -$300.8 million, which was down 8322.76% from -$301.2 million recorded in Q2 2025.
- Over the past 5 years, Iovance Biotherapeutics' Enterprise Value peaked at -$164.2 million during Q3 2024, and registered a low of -$626.3 million during Q1 2023.
- In the last 3 years, Iovance Biotherapeutics' Enterprise Value had a median value of -$301.2 million in 2025 and averaged -$323.0 million.
- As far as peak fluctuations go, Iovance Biotherapeutics' Enterprise Value skyrocketed by 5457.2% in 2024, and later tumbled by 8322.76% in 2025.
- Quarter analysis of 3 years shows Iovance Biotherapeutics' Enterprise Value stood at -$279.9 million in 2023, then fell by 15.69% to -$323.8 million in 2024, then increased by 7.09% to -$300.8 million in 2025.
- Its last three reported values are -$300.8 million in Q3 2025, -$301.2 million for Q2 2025, and -$359.7 million during Q1 2025.